[Novel vaccines. Vaccinations in the near and distant future].
Easy-to-develop vaccines usually induce antibodies against acute, self-limiting infections by stable pathogens. Today, most of these vaccines have been made, and the future diseases to tackle are more challenging: highly variable pathogens, rapidly emerging new infections with the potential of developing into pandemics, or therapeutic applications for chronic infections and cancer which most likely require complex immune responses beyond the induction of antibodies. The impact of scientific and technological progress on vaccinology has multiplied the strategies to improve vaccines. Here, we describe how genome-based approaches have revolutionized the way to identify vaccine antigen candidates, how the vast numbers of candidates can be further ranked by sophisticated gene- and protein-array based screening methods, and how surface proteomics may accelerate this target identification process. Increased structural knowledge of antigens will allow exposing or stabilizing those antigen parts relevant for protection and thereby direct the immune response to them. Improved adjuvants will enhance and bias the immune response to induce the relevant arms of the immune system. In conclusion, thanks to conceptual and biotechnological progress, future vaccines will be safer, more efficient and more complex than those today.
Wack
A
A
Division of Immunoregulation, National Institute for Medical Research, Mill Hill, NW7 1AA, London, England. awack@nimr.mrc.ac.uk
Seubert
A
A
Hilleringmann
M
M
D015195:Drug Design; D005544:Forecasting; D006801:Humans; D014611:Vaccination / Q000379:methods* / Q000639:trends*; D014612:Vaccines / Q000627:therapeutic use*; D014777:Virus Diseases / Q000517:prevention & control*
D014612:Vaccines